|Novartis announces Aliskiren will continue to be available to appropriate ... - Reuters|
Novartis International AG / Novartis announces Aliskiren will continue to be available to appropriate patients, as FDA interim assessment is concluded; product information updated . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Basel, Switzerland April 19, 2012 - Novartis announced today that the TekturnaR labels have been updated in the US, following the US Food and Drug Administration's (FDA) review of the preliminary findings from the ALTITUDE study.
The label change includes a contraindication against combined use of aliskiren-based products with angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in patients with diabetes. The FDA has also requested the inclusion of a warning against the use of aliskiren-based products in patients with moderate renal (kidney) impairment (eGFR < 60 ml/min) who are also taking an ACE inhibitor or an ARB. Aliskiren-based products will continue to be available in the US for the treatment of high blood pressure in appropriate patients.
Furthermore, and in consultation with the FDA, Novartis has decided to voluntarily cease marketing in the US of ValturnaR (aliskiren and valsartan, USP), a single pill combination of aliskiren and the ARB valsartan. Valturna sales in the US represented less than 10% of Aliskiren sales in 2011. Novartis advises US patients to seek guidance from their prescribing healthcare provider at their next (non-urgent) visit to determine appropriate alternate therapy. Novartis has also decided to voluntarily withdraw marketing authorization of the same combination pill in Switzerland, RasivalR(aliskiren and valsartan), which received marketing approval for export but was not launched.
"These decisions come after extensive discussions with the FDA and Swissmedic," said David Epstein, Division Head of Novartis Pharmaceuticals. "Patient safety continues to be our highest priority and we will continue to work with health authorities worldwide to provide aliskiren-based products to the most appropriate patient population who would benefit."
These updates follow the Novartis announcement on February 17, 2012 that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) concluded the risk-benefit review of Rasilez and combination products containing aliskiren and confirmed it remains positive in the European Union (EU) for the treatment of essential hypertension, with label changes.
About Aliskiren-based products in the US
In view of the importance of controlling high blood pressure and to enable physicians to transition patients to alternate therapies, Novartis will make Valturna available in the US until July 20, 2012. Novartis advises patients in the US to seek guidance from their prescribing healthcare provider at their next (non-urgent) visit, prior to July 20, 2012, to determine appropriate alternate therapy. Novartis will communicate to US physicians informing them of the above actions.
ALTITUDE was the first randomized, double-blind, placebo-controlled study to investigate aliskiren for more than one year in a specific population of patients with type 2 diabetes and renal impairment. These patients are known to be at high risk of cardiovascular and renal events. In the study, aliskiren was given in addition to optimal cardiovascular treatment including an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).
US Important Safety Information
TEKTURNA, TEKTURNA HCT, TEKAMLO, and AMTURNIDE are indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.
AMTURNIDE is not indicated for initial therapy of hypertension
Use TEKTURNA HCT or TEKAMLO as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Switch a patient whose blood pressure is not adequately controlled with aliskiren or hydrochlorothiazide (HCTZ) monotherapy to TEKTURNA HCT. Switch a patient whose blood pressure is not adequately controlled with aliskiren or amlodipine (or another dihydropyridine calcium channel blocker [DHP-CCB]) alone to combination therapy with TEKAMLO.
Use AMTURNIDE for patients not adequately controlled with any two of the following: aliskiren, DHP-CCB, and thiazide diuretics. Switch a patient who experiences dose-limiting adverse reactions attributed to an individual component-while on any dual combination of components of AMTURNIDE-to AMTURNIDE at a lower dose of that component to achieve similar blood pressure reductions.
TEKTURNA HCT, TEKAMLO, and AMTURNIDE may be substituted for their titrated components.
Safety and efficacy of aliskiren in pediatric patients have not been established.
Base the choice of TEKTURNA HCT or TEKAMLO as initial therapy on an assessment of potential benefits and risks. Individualize the decision to use a combination as initial therapy by weighing factors such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy.
IMPORTANT SAFETY INFORMATION
WARNING: AVOID USE IN PREGNANCY
Contraindications: Do not use aliskiren with angiotensin receptor blockers (ARBs) or ACE inhibitors (ACEIs) in patients with diabetes because of increased risk of renal impairment, hyperkalemia, and hypotension.
Angioedema: Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with aliskiren and has necessitated hospitalization and intubation. This may occur at any time during treatment and has occurred in patients with and without a history of angioedema with ACEIs or angiotensin receptor antagonists. Discontinue TEKTURNA, TEKTURNA HCT, TEKAMLO, or AMTURNIDE immediately in patients who develop angioedema, and do not readminister.
Risk of MI or Angina: Rarely, initiation or change to the dose of a calcium channel blocker has resulted in the increased frequency, duration, or severity of angina or acute myocardial infarction, particularly in patients with severe obstructive coronary artery disease.
Impaired Renal Function: Avoid use of TEKTURNA, TEKTURNA HCT, TEKAMLO, or AMTURNIDE with ARBs or ACEIs in patients with moderate renal impairment (GFR <60 mL/min). Monitor renal function periodically in patients receiving aliskiren, as changes in renal function, including acute renal failure, can be caused by drugs that affect the RAAS. Patients whose renal function may depend in part on the activity of the RAAS (eg, patients with renal artery stenosis, severe heart failure, post-MI, or volume depletion) or patients receiving ARB, ACEI or NSAID therapy may be at particular risk for developing acute renal failure on aliskiren. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function.
Hepatic Considerations: Amlodipine is extensively metabolized by the liver, and the plasma elimination half-life is 56 hours in patients with impaired hepatic function. In patients with severe hepatic impairment, start amlodipine at 2.5 mg per day, a dose not available in TEKAMLO and AMTURNIDE.
Hyperkalemia: Monitor serum potassium periodically in patients receiving aliskiren. Drugs that affect the RAAS can cause hyperkalemia. Risk factors for the development of hyperkalemia include renal insufficiency, diabetes, and combination use of aliskiren with ARBs or ACEIs, NSAIDs, potassium supplements, or potassium-sparing diuretics.
Cyclosporine, Itraconazole, or Lithium: Avoid use of TEKTURNA, TEKTURNA HCT, TEKAMLO, or AMTURNIDE with cyclosporine or itraconazole. Additionally, avoid use of TEKTURNA HCT or AMTURNIDE with lithium.
Important Considerations Due to the HCTZ Component: Hypersensitivity reactions to HCTZ may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in those with such a history. Thiazides have been reported to cause exacerbation or activation of systemic lupus erythematosus.
Common AEs: Adverse events (AE) with increased rates for TEKTURNA compared with placebo included: diarrhea (2.3% vs 1.2%), cough (1.1% vs 0.6%), rash (1.0% vs 0.3%), elevated uric acid (0.4% vs 0.1%), gout (0.2% vs 0.1%), and renal stones (0.2% vs 0%).
Adverse events with increased rates for TEKTURNA HCT compared with placebo included: dizziness (2.3% vs 1.0%), influenza (2.3% vs 1.6%), diarrhea (1.6% vs 0.5%), cough (1.3% vs 0.5%), vertigo (1.2% vs 0.5%), asthenia (1.2% vs 0%), and arthralgia (1.0% vs 0.5%).
The AE in a placebo-controlled trial that occurred in at least 2% of patients treated with TEKAMLO and at a higher incidence than placebo was peripheral edema (6.2% vs 1.0%). The incidence of peripheral edema at high dose was 8.9%.
The most common AEs in a short-term controlled trial that occurred in at least 2% of patients treated with AMTURNIDE were peripheral edema (7.1%), dizziness (3.6%), headache (3.6%), and nasopharyngitis (2.6%).
Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.
# # #
Novartis Media Relations
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
Novartis Investor Relations
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
Source: Novartis International AG via Thomson Reuters ONE
--- End of Message ---
Novartis International AG
WKN: 904278;ISIN: CH0012005267;